The label does not include JAK-like black-box warnings or usage restrictions, validating BMY’s contention that Sotyktu's TYK2 target is well differentiated from JAK1/2/3.
BMY expects eventual Sotyktu approval in other autoimmune indications and foresees peak annual sales of at least $4B.